Novo Nordisk Strikes $2B Deal for Obesity Drug
Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by ...
Novo Signs $2 Billion Deal With United Labs for Obesity Drug
Novo Nordisk A/S agreed to pay United Laboratories International Holdings as much as $2 billion for a next-generation obesity ...
Novo Nordisk to Pay Up to $2 Billion for Chinese Weight-Loss Drug License, Stock Drops
Novo Nordisk said Monday that it had entered into a license agreement with a Chinese company developing a competitor to ...
Germany's SAP overtakes Novo Nordisk as Europe's largest company
German software company SAP overtook Danish healthcare company Novo Nordisk as Europe's largest company by market cap on ...
Lilly, Novo expand DTC reach of obesity meds after compound win
Eli Lilly and Novo Nordisk have scored big wins from the FDA in recent months, as the agency cracks down on copycat versions of their GLP-1 blockbusters. Now, as the battle with compound GLP-1s comes ...
Novo Nordisk's next-gen obesity drug CagriSema had investors excited. Now they're not so sure
Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...